| 20.01 0 (0%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 23.67 | 1-year : | 27.65 |
| Resists | First : | 20.27 | Second : | 23.67 |
| Pivot price | 19.92  |
|||
| Supports | First : | 19.89 | Second : | 19.67 |
| MAs | MA(5) : | 19.97 |
MA(20) : | 19.89 |
| MA(100) : | 18.93 |
MA(250) : | 14.28 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.6  |
D(3) : | 50.8 |
| RSI | RSI(14): 56.7 | |||
| 52-week | High : | 23.4 | Low : | 5.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OMIC ] has closed below upper band by 12.1%. Bollinger Bands are 94.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.03 - 20.14 | 20.14 - 20.23 |
| Low: | 19.75 - 19.88 | 19.88 - 19.98 |
| Close: | 19.81 - 20.02 | 20.02 - 20.19 |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Fri, 21 Feb 2025
Singular Genomics Announces Closing of Acquisition by Deerfield Management - The Globe and Mail
Fri, 21 Feb 2025
Singular Genomics Systems, Inc. Closes Acquisition by Deerfield Management Company - Nasdaq
Fri, 21 Feb 2025
Singular Genomics' Next Chapter: New CEO Takes Helm as $20/Share Deerfield Deal Closes - Stock Titan
Wed, 19 Feb 2025
Singular Genomics Shareholders Approve Merger Agreement - Investing.com
Tue, 28 Jan 2025
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, CCRN, OMC on Behalf of Shareholders - GlobeNewswire
Fri, 17 Jan 2025
OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.84e+006 (%) |
| Held by Institutions | 14.1 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.709e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 450.9 % |
| Return on Equity (ttm) | -24.3 % |
| Qtrly Rev. Growth | 2.67e+006 % |
| Gross Profit (p.s.) | -6.58 |
| Sales Per Share | -29.12 |
| EBITDA (p.s.) | -733696 |
| Qtrly Earnings Growth | -34.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.69 |
| Price to Cash Flow | 0.74 |
| Dividend | 0 |
| Forward Dividend | 44740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|